Aug 14, 2020
Soligenix Announces Recent Accomplishments And Second Quarter 2020 Financial Results
Jun 22, 2020
Soligenix to Join Russell Microcap® Index
Jun 09, 2020
Soligenix to Present at the MedInvest Infectious Disease and Immunology Investor Conference
May 15, 2020
Soligenix Announces Recent Accomplishments And First Quarter 2020 Financial Results
May 07, 2020
Soligenix Receives $840,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
Apr 30, 2020
Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma
Apr 06, 2020
Soligenix Receives European Patent for Therapeutic Use of Synthetic Hypericin to Treat Cutaneous T-Cell Lymphoma
Feb 03, 2020
Soligenix Announces Japanese Patent Allowance for Use of Dusquetide in Oral Mucositis
Jan 30, 2020
Soligenix to Present at the 22nd Annual BIO CEO & Investor Conference
Jan 14, 2020
Soligenix - Advancing to Important Inflection Points With Two Pivotal Phase 3 Clinical Trials
Dec 18, 2019
Soligenix to Receive $850,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
Nov 25, 2019
Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference
Nov 19, 2019
Forward Science And The TeleDentists Announce A SalivaMAX Sponsorship Agreement
Nov 18, 2019
Soligenix to Present at the PCG Spotlight Series Conference
Nov 12, 2019
Soligenix Announces Recent Accomplishments And Third Quarter 2019 Financial Results
Nov 06, 2019
Soligenix to Present at the 25th Annual BIO-Europe International Partnering Conference
Oct 24, 2019
Soligenix Receives US Patent for Improved Production of Synthetic Hypericin Composition
Oct 03, 2019
Soligenix to Present at the 20th Annual GCFF Investor Conference in Vancouver, British Columbia, Canada
Aug 28, 2019
Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer
Aug 15, 2019
Soligenix Announces $150,000 NIH Small Business Innovation Research Award Supporting Evaluation of SGX942 in Pediatric Indications